PainExhibit,com, 9008 El Cajon Way, #4, Sacramento, CA, 95826, USA.
Harm Reduct J. 2012 Jan 1;9:1. doi: 10.1186/1477-7517-9-1.
Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids may be recommended as a second-line pharmacotherapy but have risks including overdose and death. Cannabis has been shown to be effective for treating nerve pain without the risk of fatal poisoning. The author suggests that physicians who treat neuropathic pain with opioids should evaluate their patients for a trial of cannabis and prescribe it when appropriate prior to using opioids. This harm reduction strategy may reduce the morbidity and mortality rates associated with prescription pain medications.
神经性疼痛影响美国人口的 5%至 10%，且可能对治疗有抗药性。阿片类药物可能被推荐作为二线药物治疗，但存在包括过量和死亡在内的风险。大麻已被证明对治疗神经痛有效，且没有致命中毒的风险。作者建议，用阿片类药物治疗神经性疼痛的医生应该评估他们的患者是否适合试用大麻，并在使用阿片类药物之前酌情开出大麻处方。这种减少伤害的策略可能会降低与处方止痛药相关的发病率和死亡率。
